Urology Devices Market worth $46.4 billion by 2026 - Exclusive Report by MarketsandMarkets™1/31/2022 According to the new market research report "Urology Devices Market by Product ((Dialysis, Endoscopes, Lasers, Lithotripsy, Robotic System), (Guidewires, Catheters, Stents)), Application(Kidney Diseases, Urological Cancer, BPH), End User(Hospital, Dialysis Center, Homecare) - Global Forecast to 2026", published by MarketsandMarkets™, the market is projected to reach USD 46.4 billion by 2026 from USD 38.0 billion in 2021, at a CAGR of 4.1%.
Browse in-depth TOC on "Urology Devices Market" 122 – Tables 36 – Figures 198 – Pages Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173062212 The rising incidence and prevalence of urological conditions drives growth in the urology devices market, growing preference for minimally invasive procedures, and the growing number of hospitals and investments in endoscopy and laparoscopy facilities are among the other factors. Emerging economies such as China and Japan are providing lucrative opportunities for the players operating in the market. The instruments segment accounted for the largest share of the urology devices market, by product segment, in 2020 Based on product, the market is segmented into instruments and consumables & accessories. The instruments segment accounted for the largest share of the market in 2020. This segment includes dialysis devices, endoscopes, laser and lithotripsy devices, robotic systems, endovision and imaging systems, insufflators, endoscopy fluid management systems, and urodynamic systems. The dialysis devices segment accounted for the largest share of the urology instruments market in 2020. The large share of this segment can be attributed to the growing patient pool of CKD due to the rising geriatric population. Urological cancer and BPH segment to register the highest growth rate during the forecast period The urology devices market is segmented into kidney diseases, urological cancer and BPH, pelvic organ prolapse, and other applications based on application. In 2020, the urological cancer and BPH segment accounted for the highest growth rate. This can be attributed to the rising incidence of urological cancers coupled with the growing number of cancer-related surgeries. The hospitals, ASCs, and clinics segment accounted for the largest share of the urology devices market, by end user segment, in 2020 Based on end users, the market is segmented into hospitals, ASCs, and clinics; dialysis centers; and home care settings. In 2020, the hospitals, ASCs, and clinics segment accounted for the largest share of the market. The improving healthcare infrastructure in developing countries such as India, the rising number of target procedures, and the rising number of surgeries are the major factors driving this segments growth. Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=173062212 North America is the largest regional market for urology devices market the market is segmented into five regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the urology devices market. The large share of this region can be attributed to the increasing healthcare expenditure, highly developed healthcare systems in the US and Canada, and increasing prevalence of chronic and lifestyle conditions. The major players operating in this urology devices market are Fresenius Medical Care AG & Co. KGaA (Germany), Baxter International Inc. (US), Boston Scientific Corporation (US), Becton, Dickinson and Company (US), Olympus Corporation (Japan), B. Braun Melsungen AG (Germany), Stryker Corporation (US), KARL STORZ (Germany), Cook Medical (US), Intuitive Surgical (US), Medtronic plc (Ireland), Cardinal Health (US), Teleflex Incorporated (US), Richard Wolf GmbH (Germany), CompactCath (US), Dornier MedTech (Germany), Nikkiso Co., Ltd. (Japan), Balton Sp. z o.o. (Poland), Dialife SA (Switzerland), Maxer Endoscopy GmbH (Germany), Vimex Sp. z o.o. (Poland), Amsino International, Inc. (US), ROCAMED (Monaco), Well Lead Medical Co., Ltd. (China), Medispec (US), Medical Technologies of Georgia (Georgia), EndoMed Systems GmbH (Germany), Hunter Urology (England), J and M Urinary Catheters LLC (US), and Ribbel International Limited (India). Browse Related Reports: Urinary Catheters Market by Product (Indwelling, Intermittent, External), Type (Coated, Uncoated), Application (Urinary Incontinence, Benign Prostate Hyperplasia, General Surgery), Usage (Male, Female), End Users (Hospitals) - Global Forecast to 2025 https://www.marketsandmarkets.com/Market-Reports/urinary-catheter-market-132934629.html
0 Comments
According to the new market research report "Digital X-ray Market by Portability (Fixed, Portable), Applications (General, Dental, Mammography, Cancer, Fluoroscopy), Technology (Direct, Computed), System (Retrofit, New), End Users, Price Range, Type, and Region - Global Forecast to 2026", published by MarketsandMarkets™, the market is expected to reach USD 16.4 billion by 2026 from an estimated USD 11.1 billion in 2021, at a CAGR of 8.1% from 2021 to 2026.
Browse in-depth TOC on "Digital X-ray Market" 230 – Tables 45 – Figures 280 – Pages Download PDF Brochure: :-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1164 The major factors driving the growth of this market include the increasing geriatric population and growth in disease incidence as well as favorable government regulations, investments, and initiatives. The advantages of digital X-ray systems have played a key part in their adoption; their speed and accuracy, as well as quick processing times, allow for significantly higher patient screening volumes than earlier. This has pushed companies to focus on product development and innovation. The direct radiography segment dominated the digital X-ray market in 2020 Based on technology, the market is segmented into direct radiography and computed radiography. The direct radiography segment commanded the largest share of the global market in 2020. The major benefit of DR-based systems over film and CR systems is that images are sent directly to a computer screen from the X-ray imaging plate, thereby eliminating the need to retrieve the image plate for processing images or taking a second X-ray shot. An effective dynamic range, better medical evaluation, superior and accurate image capture, reduced radiation exposure for patients and workers, flexibility in image management, improved patient throughput, superior evaluation of data and images, and lower operational costs are some of the other advantages of DR systems. Due to these advantages, the use of DR systems is on the rise. Portable digital X-ray systems are expected to register the highest CAGR during the forecasted period Based on portability, the digital X-ray market is segmented into fixed digital X-ray systems and portable digital X-ray systems. Fixed digital X-ray systems include floor-to-ceiling-mounted systems and ceiling-mounted systems, while portable digital X-ray systems include mobile X-ray systems and handheld X-ray systems. The portable digital X-ray systems are expected to grow with the highest CAGR during the forecasted period. Portable X-ray systems are light and can be transported to any desired location. These systems are especially useful in a variety of radiographic imaging set-ups, including intensive care units, cardiac care units, neonatal intensive care units, operating rooms, emergency rooms, and at the patient's bedside for critically ill patients or patients with mobility challenges. Request Sample Pages: :-https://www.marketsandmarkets.com/requestsampleNew.asp?id=1164 The retrofit digital X-ray systems segment dominated the digital X-ray market in 2020 The global digital X-ray systems market is divided into new and retrofit digital X-ray systems. The retrofit digital X-ray systems segment is expected to dominate the market during the forecast period. The large share of this segment can be attributed to the greater adoption of retrofit systems among end users due to their lower cost compared to new digital X-ray systems. Hospitals were the key end-users in the digital X-ray market in 2020 Based on end users, the X-ray market is segmented into diagnostic centers, hospitals, and dental care centers. Hospitals are expected to dominate the market during the forecast period. Hospitals constantly require advanced diagnostic systems that enable the screening and diagnosis of a large number of patients in a short time period. This is a key factor driving market growth. The general applications segment dominated the digital X-ray market by applications in 2020 Based on applications, the market is segmented into general radiography, dental applications, fluoroscopy, cancer, and mammography applications. The general radiography segment is expected to dominate this market during the forecast period. Growth in this market can be attributed to the increasing prevalence of target diseases, high demand for early diagnosis and diagnostic imaging, and technological advancements in the digital X-ray systems market. Speak to Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=1164 Asia Pacific is expected to see the highest growth in the digital X-ray market by region The digital X-ray market is segmented into five major regions—North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest regional market for digital X-ray systems, whereas the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. Growth in the digital X-ray market in the Asia Pacific is mainly driven by the growing geriatric population, particularly in Japan; increasing disposable incomes, allowing for greater affordability for advanced technologies; the rising prevalence of target diseases; and favorable government initiatives. Such factors help to drive the market for digital imaging systems in this region and draw foreign investments and partnerships. The digital X-ray market is dominated by Siemens Healthineers (Germany), GE Healthcare (US), Koninklijke Philips N.V. (Netherlands), FUJIFILM Holdings Corporation (Japan), and Canon, Inc. (Japan). The other leading market players include Carestream Health (US), Shimadzu Corporation (Japan), Hologic Inc. (US), Agfa-Gevaert Group (Belgium), Samsung Medison (South Korea), and Konica Minolta (Japan). Browse Related Reports: Nuclear Imaging Equipment Market by Product (SPECT (Hybrid SPECT, Standalone SPECT), Hybrid PET, & Planar Scintigraphy), Application (Oncology, Cardiology & Neurology) & End user (Hospitals, Imaging Centers) - Global Forecasts to 2025https://www.marketsandmarkets.com/Market-Reports/nuclear-imaging-equipment-market-98.html CBCT/Cone Beam Imaging Market by Application (Dental (Oral and Maxillofacial Surgery, Implantology, Orthodontics, Endodontics), Patient Position (Standing/Sitting, Seated, Supine), End User (Hospital, Private Practice) - Global Forecast to 2021https://www.marketsandmarkets.com/Market-Reports/cone-beam-imaging-market-226049013.html According to the new market research report "High-Throughput Screening (HTS) Market by Product (Instruments, Software, Service), Technology (Cell-Based Assays, Label-Free), Application (Drug Discovery, Biochemical Screening, Research), End User (Pharma & Biotech, CROs)- Global Forecast to 2025", published by MarketsandMarkets™, the global High-Throughput Screening Market size is projected to reach USD 26.4 billion by 2025 from USD 15.3 billion in 2020, at a CAGR of 11.5% during the forecast period.
Browse in-depth TOC on "High-Throughput Screening (HTS) Market" 432 – Tables 40 – Figures 319 – Pages Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134981950 The HTS Market growth is driven mainly by factors such as increasing R&D spending by pharmaceutical & biotechnology companies, technological advancements in high-throughput screening market and the availability of government funding & venture capital investments. Emerging markets and growing applications in life sciences research are also factors expected to provide growth opportunities for players in the market. The consumables segment accounted for the largest share of the product & services segment in the high-throughput screening market in 2019. On the basis type of product & service, the HTS Market is broadly segmented into consumables , instruments, services, and software. In 2019, consumables accounted for the largest share of the high-throughput screening (HTS) market. This can primarily be attributed to the wide use of reagents & assay kits in HTS techniques, increasing pharmaceutical R&D, and rising government funding for life sciences research. The drug discovery segment accounted for the largest share of the application segment in the high-throughput screening market in 2019. Based on application, the HTS Market is categorized into four segments—drug discovery, biochemical screening, life sciences, and other applications. The drug discovery application segment accounted for the largest share of the market in 2019. The key factor driving this segments growth is the increasing number of clinical trials and rising pharmaceutical R&D expenditure. Request Sample Pages:-https://www.marketsandmarkets.com/requestsampleNew.asp?id=134981950 The Asia Pacific region is the fastest-growing region of the high-throughput screening market in 2019. In 2019, Asia Pacific region accounted for the fastest-growing region of the HTS Market. It is also estimated to grow at the highest CAGR in the market during the forecast period, this is mainly due to factors such as the rising R&D spending, growing public-private partnerships, and increasing government funding are factors driving the growth of the market in this region. Some of the prominent players in the high-throughput screening market are Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Danaher Corporation (US), PerkinElmer, Inc. (US), Tecan Group Ltd. (Switzerland), AXXAM S.p.A. (Italy), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Promega Corporation (US), Corning Incorporated (US), and Eurofins Scientific (Luxembourg). Browse Related Reports: Cell Analysis Market by Product [Microscope, Spectrophotometers, Flow cytometry (Software, Accessories)], Process (Cell Viability, Cell Proliferation, Signal Transduction), End User (Pharma, Research, Biotechnology Companies) - Global Forecast to 2024https://www.marketsandmarkets.com/Market-Reports/cell-analysis-market-157543946.html Mycoplasma Testing Market worth $1,095 million by 2025 - Exclusive Report by MarketsandMarkets™1/26/2022 According to the new market research report "Mycoplasma Testing Market by Product & Service (Assays, Kits, Reagents), Technique (NAT, ELISA, Staining), Application (Cell Line, End of Production Testing), End User (Biopharmaceutical, Cell Banks, CROs), Region - Global Forecast to 2025", published by MarketsandMarkets™, the Mycoplasma Testing Market is projected to reach USD 1,095 million by 2025 from USD 689 million in 2020, at a CAGR of 9.7%.
Browse in-depth TOC on "Mycoplasma Testing Market" 111 – Tables 37 – Figures 154 – Pages Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=136509856 The global mycoplasma testing markets growth is driven by factors such as the growing concerns over cell culture contamination, growth in the pharmaceutical and biotechnology industries, and rising pharmaceutical R & D activities and investments. The assays, kits, & reagents products segment accounted for the largest share of the mycoplasma testing market, by product & service segment, in 2019 The mycoplasma testing market is segmented into assays, kits, & reagents; instruments; and services based on product & service. In 2019, the assays, kits, & reagents segment accounted for this markets largest share. The frequent purchase of these consumables compared to instruments and the increasing use of kit-based techniques for mycoplasma testing are the essential factors driving this market segments growth. Cell line testing segment to register the highest growth rate during the forecast period Based on application, the mycoplasma testing market is segmented into cell line testing, virus testing, and end-of-production cell testing. In 2019, the cell line testing segment accounted for the largest share of this market. Factors such as the rapid growth in the biopharmaceutical industry and the increasing demand for monoclonal antibodies drive this market segments growth. Get 10% Customization on this Research Report: -https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=136509856 North America is the largest regional market for mycoplasma testing market The global mycoplasma testing market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2019, North America accounted for the largest share of the global mycoplasma testing market. The large share can be attributed primarily to the growth in biotechnology and pharmaceutical industries, the high adoption rate of novel technologies, and the large number of life science research studies conducted in this region. The major players operating in this market are Thermo Fisher Scientific, Inc. (US), Charles River Laboratories International, Inc. (US), Lonza Group Ltd. (Switzerland), Merck KGaA (Germany), Roche Diagnostics (Switzerland), American Type Culture Collection (US), Bionique Testing Laboratories, Inc. (US), InvivoGen (US), PromoCell GmbH (Germany), Biological Industries Israel Beit Haemek Ltd. (Israel), Creative Bioarray (US), Mycoplasma Experience (UK), Norgen Biotek Corp. (Canada), Agilent Technologies (US), Biotools B & M Labs, S.A. (Spain), Eurofins Scientific (Luxembourg), GeneCopoeia, Inc. (US), GenBio (Canada), Minerva Biolabs GmbH (Germany), Meridian Bioscience, Inc. (US), Sartorius AG (Germany), Savyon Diagnostics (Israel), Nelson Laboratories Fairfield, Inc. (US), Clongen Laboratories, LLC (US), and ScienCell Research Laboratories, Inc. (Canada). Browse Related Reports: Blood Screening Market by Technology (Nucleic Acid Amplification, (Real Time PCR), ELISA (Chemiluminescence immunoassay), Rapid Test, Western Blot), Product (Instrument, Reagent & Kits, Software) & End User (Blood Bank, Hospital) - Global Forecast to 2025 https://www.marketsandmarkets.com/Market-Reports/blood-screening-market-267747042.html In-Vitro Diagnostics Market by Product & Service (Instrument, Kits), Technology (Immunoassay, MDx, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) End User (Hospitals) - Global Forecast to 2025https://www.marketsandmarkets.com/Market-Reports/ivd-in-vitro-diagnostics-market-703.html According to a new market research report "Preimplantation Genetic Testing Market by Type (Genetic Diagnosis/Genetic Screening), Technology (NGS, PCR, FISH, CGH, SNP), Products & Services, Application (Aneuploidy, Translocations), End User (Fertility Clinics, Research) - Forecast to 2022", published by MarketsandMarkets™, the Global Preimplantation Genetic Testing Market is projected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%.
Browse and in-depth TOC on " Preimplantation Genetic Testing Market " 85 - Tables 42 - Figures 204- Pages Download PDF Brochure:- http://www.marketsandmarkets.com/pdfdownload.asp?id=605 By application, the aneuploidy segment is expected to be the fastest growing segment in the forecast period The aneuploidy segment is expected to grow at the fastest CAGR. Growth of this segment can be attributed to the increasing maternal age, rising incidence of aneuploidy disorders, and strategic initiatives by key players to provide technologically advanced PGS products for aneuploidy screening. Aneuploidy screening has been reported to increase the chance of successful embryo implantation, decreases miscarriage rate, and reduce the chance of having a child with a chromosome abnormality). North America dominated the market in 2016 Geographically, the Preimplantation Genetic Testing Market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest share of the market in 2016, followed by Europe. Rising number of IVF procedures (with decreasing fertility rates), significant adoption of genomic techniques, ongoing trend of replacing traditional genomic technologies with advanced and innovative genetic techniques (such as FISH and NGS), and increasing private-public funding to develop and commercialize novel PGS & PGD procedures are the key factors that account for the larger share of the Preimplantation Genetic Testing Market in North America. Talk To Our Research Analysts: -http://www.marketsandmarkets.com/speaktoanalyst.asp?id=605 As of 2016, the major product manufacturers operating in the global Preimplantation Genetic Testing Market included Illumina, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Rubicon Genomics, Inc. (U.S.), Oxford Gene Technology (U.K.), Yikon Genomics (China), and SciGene Corporation (U.S.), among others. Moreover, as of 2016, major service providers active in the global market included Beijing Genomics Institute (BGI) (China), Good Start Genetics (U.S.), CombiMatrix Corporation (U.S.), Genea Limited (Australia), Invicta Genetics (Poland), and Progenesis (U.S.). Wearable Injectors Market worth $11.5 billion by 2026 - Exclusive Report by MarketsandMarkets™1/24/2022 According to the new market research report "Wearable Injectors Market by Product Type(On-Body and Off-Body), Therapy (Immuno-oncology, Diabetes, Cardiovascular diseases), Technology(Spring-based, Motor Driven, Rotary Pump, Expanding Battery), Care Setting (Hospitals) - Global Forecast to 2026", published by MarketsandMarkets™, the global market is projected to reach USD 11.5 billion by 2026 from USD 7.2 billion in 2021, at a CAGR of 9.9% during the forecast period.
Browse in-depth TOC on "Wearable Injectors Market" 114 – Tables 51 – Figures 196 – Pages Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=100771004 The Growth in this market is mainly driven by factors such as the shift of healthcare delivery toward homecare due to COVID-19, advantages of wearable injectors in the administration of various drugs, the rising prevalence of chronic diseases (such as cancer, diabetes, and CVD), favorable reimbursement scenario in major markets, and technological advancements in injector devices. However, the preference for alternative drug delivery modes, high costs, and a poor reimbursement structure in developing countries are expected to limit the adoption of wearable injectors to a certain extent. By Type, the on-body injectors segment is expected to account for the largest share of the wearable injectors market By type, the global market is segmented into on-body injectors and off-body injectors. The on-body injectors segment accounted for the largest share in the forecast year. The large share of this segment can be attributed to the patients ease to deliver a precise amount of drug to the body over a controlled period of time. On the basis of technology, spring based segment is expected to account for the largest share of the market Based on technology, the wearable injectors market is segmented into spring-based, motor-driven, rotary pump, expanding battery, and other technologies. The spring-based technology segment accounted for the largest share in the forecast period. The large share of this segment can be attributed to the rising demand for adhesive patches, as these devices are user-friendly and enable patients to accurately deliver the required drug subcutaneously. Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=100771004 On the basis of therapy, diabetes segment is expected to account for the largest share of the market Based on therapy, the wearable injectors market is segmented into immuno-oncology, diabetes, cardiovascular diseases, and other therapies (such as Parkinson's disease, thalassemia, and primary immunodeficiency disorders). The diabetes segment accounted for the largest share in the forecast period. The large share of this segment can be attributed to The high burden of diabetes across the globe, coupled with the growing availability of wearable injectors for the treatment of these diseases, is driving the growth of this market segment. On the basis of end user, hospitals and clinics segment holds the highest market share in the wearable injectors market Based on end user, the market is segmented into hospitals and clinics and home healthcare settings. The hospitals and clinics segment accounted for a larger market share during the forecast period. The large share of this segment can primarily be attributed to the rising preference for the self-administration of medication and the increasing need to curb healthcare costs. In addition, the growing demand for technologically developed drug delivery approaches, which lower the hospitalization rate and require minimal expertise, is expected to boost the growth of the home healthcare settings segment. Speak to Analyst :-https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=100771004 North America to dominate the wearable injectors market during the forecast period The wearable injector market in North America accounted for the largest market during the forecast period. The large share of North America in this market is to the rising prevalence of chronic and lifestyle-related diseases and the presence of advanced healthcare infrastructure in the region. However, the Europe market is estimated to grow at the highest CAGR during the forecast period owing to factors such as the Increasing prevalence of chronic diseases, Government support for drug development in Germany, Rising focus on biosimilar innovation in the UK, Favorable reimbursement scenario for various treatment options in France. Prominent players in the wearable injectors market include Becton, Dickinson and Company(US), Ypsomed(Switzerland), Amgen(US), Subcuject(Denmark), Enable Injections, Inc(US), Medtronic Plc(Ireland), Insulet Corporation(US), United Therapeutics Corp (Us), CeQur SA(Switzerland), Sensile Medical(Switzerland). Browse Related Reports: Insulin Delivery Devices Market by Type (Insulin Pens (Reusable, Disposable), Insulin Pumps (External/Tethered, Patch), Pen Needles (Standard, Safety), Insulin Syringes) and End User (Patients/Homecare, Hospitals & Clinics) - Global Forecast to 2021https://www.marketsandmarkets.com/Market-Reports/insulin-delivery-device-market-107632092.html Healthcare CRM Market Worth $17.4 Billion by 2023 - Exclusive Report by MarketsandMarkets™1/20/2022 According to the new market research report "Healthcare CRM Market by Component (Software, Service), Delivery (On premise, Cloud, Public, Private, Hybrid), End user (Hospital, ASC, Payers, Life Science), Functionality (CSS, Marketing, Sales, Digital Marketing, AI, Analytics) - Global Forecast to 2023", published by MarketsandMarkets™, the Healthcare CRM Market is projected to reach USD 17.4 billion by 2023 from USD 8.8 billion in 2018, at a CAGR of 14.6% during the forecast
Browse in-depth TOC on "Healthcare CRM Market" 62 - Tables 34 - Figures 121 - Pages Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=88873203 The benefits of CRM software and a growing focus on patient engagement are the major factors driving the growth of the Healthcare CRM Market. Healthcare providers are expected to dominate the healthcare CRM end-user market in 2018 Based on end user, the Healthcare CRM Market is segmented into healthcare providers, the life sciences industry, and healthcare payers. The healthcare providers segment is estimated to account for the largest share of the Healthcare CRM Market in 2018. This segment is also expected to register the highest CAGR during the forecast period. Healthcare providers need to interact with multiple stakeholders, including patients, physicians, other referral healthcare organizations, healthcare payer organizations, pharmaceutical companies, and consumers/potential patients, and each requires unique CRM strategies and solutions. Moreover, there is a growing focus on patient engagement, which is again likely to drive the market for this segment. Healthcare CRM services to grow at the highest CAGR during 2018-2023 On the basis of component, the Healthcare CRM Market is segmented into software and services. The services segment is expected to dominate the Healthcare CRM Market in 2018. This segment is also expected to register the highest CAGR during the forecast period. Services form a large component of the Healthcare CRM Market primarily due to the indispensable role of service providers when it comes to the use of CRM solutions for healthcare. In terms of IT usage and skills, the healthcare industry is still in the nascent stage; it relies heavily on service providers for CRM-related services and support services, such as implementation, integration, training and education, maintenance, and technology upgrades. The recurring need for services such as software upgrades and maintenance is the key factor supporting the growth of this segment. Request for Sample Report -https://www.marketsandmarkets.com/requestsampleNew.asp?id=88873203 North America to dominate the market, followed by Europe Geographically, the global Healthcare CRM Market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is estimated to hold the largest share of the Healthcare CRM Market. Some of the major factors driving the growth of this market include government initiatives and regulations to encourage the adoption of healthcare IT, growing pressure on healthcare organizations to focus on patient engagement for patient retention, growing EHR adoption, growing focus of CRM providers on developing and commercializing AI and analytics-powered advanced CRM solutions, and the increasing number of ACOs. However, the market in Asia is estimated to grow at the highest CAGR during the forecast period. Factors such as the improving quality of healthcare, improvements in healthcare systems, the growing medical tourism market in Asian countries, and increasing government initiatives are the key factors driving the growth of this market. The key players in the Healthcare CRM Market are Salesforce.com, Inc. (US), SAP SE (Germany), Oracle (US), Microsoft (US), IBM (US), Influence Health (US), SugarCRM (US), Accenture (Ireland), Healthgrades (US), and Infor, Inc. (US). Browse Related Reports: Healthcare EDI Market by Component (Solution, Service), Delivery Mode (On-premise & Cloud, Mobile) Transaction Type (Claims Management, Payment Remittance, Payments, Healthcare Supply Chain), End-User - Global Forecast to 2025https://www.marketsandmarkets.com/Market-Reports/healthcare-edi-market-130571438.htmlRevenue Cycle Management/RCM Market by Product & Services (Eligibility Verification, Clinical Coding, CDI, Claims Processing, Denial Management, Outsourcing Services, Cloud), End User(Payers, Hospitals, Outpatient), Covid-19 Impact - Global Forecast to 2026https://www.marketsandmarkets.com/Market-Reports/revenue-cycle-management-market-153900104.html According to the new market research report "Laboratory Proficiency Testing Market by Industry (Clinical Diagnostics (Routine Chemistry), Microbiology (Pathogens, Sterile Tests), Food, Animal Feed (Fish, Vegetable), Commercial Beverage (Alcohol), Water, Technology (PCR,)) - Global Forecast to 2024", published by MarketsandMarkets™, the Laboratory Proficiency Testing Market is projected to reach USD 1,103 million by 2024 from USD 800 million in 2019, at a CAGR of 6.6% during the forecast period.
Browse in-depth TOC on Laboratory Proficiency Testing Market 249 – Tables 29 – Figures 310 – Pages Download PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144227949 Proficiency testing forms an essential precondition for operational excellence and accreditation in several industries. This is one of the major factors driving the growth of the proficiency testing market, globally. Also, the stringent safety and quality regulations for food and pharmaceutical products and the increasing focus on water testing are the other major factors supporting market growth. The cannabis/opioids proficiency testing segment is estimated to grow at the highest CAGR in the laboratory proficiency testing market, by industry, during the forecast period In the laboratory proficiency testing market, by industry, the cannabis/opioids proficiency testing segment is estimated to grow at the highest CAGR during the forecast period. Growth in this segment is primarily driven by the legalization of medical cannabis, growing number of cannabis testing laboratories, rising awareness about the medical use of cannabis, and the increasing availability of analytical testing instruments and software. Get 10% Free Customization on this Report:-https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=144227949 The proficiency testing market for chromatography is estimated to grow at the highest CAGR in the laboratory proficiency testing market, by technology, during the forecast period In the laboratory proficiency testing market, by technology, the chromatography segment is expected to grow at the highest CAGR during the forecast period. Chromatography is used to carry out complicated separations like amino acid sequencing or pollutant separations, based on differential partitioning between the mobile and stationary phase. The advantages associated with chromatographic testing, such as the increased safety, reliability, and transparency of the pharmaceutical supply chain by testing the identity, strength, purity, quality, and potency of a drug product, and the growth in the pharmaceutical industry as a whole are the major factors driving the growth of this segment. The Asia Pacific region holds high growth potential in the laboratory proficiency testing market The Asia Pacific is considered to be the most attractive regional market for laboratory proficiency testing owing to the large base of manufacturers and research laboratories in the region. Also, the growing scientific base and research capabilities in several Asian countries; growth of the Asian pharmaceutical, food, and biologics markets; and the large base of CROs in the region are some of the other major factors driving market growth in the region. The prominent players operating in the global laboratory proficiency testing market are LGC Limited (UK), Bio-Rad Laboratories (US), Randox Laboratories (UK), Merck (Germany), College of American Pathologists (US), American Proficiency Institute (US), Waters Corporation (US), QACS (Greece), FAPAS (UK), AOAC (US), Phenova Inc. (US), Weqas (Cardiff), Advanced Analytical Solutions, LLC (UK), Bipea (France), Absolute Standards Inc. (US), and NSI Lab Solutions (US). Patient Registry Software Market worth $2.8 billion by 2026 - Exclusive Report by MarketsandMarkets™1/18/2022 According to the new market research report "Patient Registry Software Market by Type of Registry (Diabetes, Cancer, Rare Disease, Asthma, Kidney), Software (Integrated and Standalone), Delivery (On Premise and Cloud), Pricing Model, Database (Public), End User (Hospitals) - Global Forecast to 2026," published by MarketsandMarkets™, the Patient Registry Software Market is projected to reach USD 2.8 billion by 2026 from USD 1.4 billion in 2021, at a CAGR of 15.0% during the forecast period.
Browse in-depth TOC on "Patient Registry Software Market" 224 – Tables 45 – Figures 286 – Pages Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144694594 The growth of this market is mainly attributed to the shift toward computerized registries to provide users with an automated way to store data and create, sort, and display patient lists for use in planning, quality improvement, reporting, and direct care delivery. Also, the emergence of the COVID-19 pandemic and the increasing number of COVID-19 patients globally are expected to increase the demand for patient registry software in the coming years. The base year considered for the study is 2020, while, the forecast period is 2021 to 2026. By type of registry, the disease registries segment accounted for the largest share of the patient registry software market in 2020. On the basis of type of registry, the disease registries segment accounted for the largest share of the patient registry software market in 2020. The large share of this segment can be attributed to the increase in the aging population, rising prevalence of chronic and rare & new diseases, growing awareness on the role of registries in health management, and the adoption of EHRs across the globe. The hospitals & medical practices segment is expected to witness the highest growth rate in the patient registry software market, by end user, during the forecast period Based on end user, the hospitals & medical practices segment is expected to register the highest CAGR during the forecast period. Factors responsible for the growth of this segment are growing prevalence of research, QM and improvement, facility planning and marketing, and monitoring patient outcomes. Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=144694594 North America dominated the patient registry software market in 2020 North America accounted for the largest share of the market in 2020, followed by Europe and Asia Pacific. The increasing need to integrate healthcare systems, government funding for developing patient registries, rising focus on PHM and HIE, increasing adoption of HCIT as a cost-containment measure are some of the factors driving the growth of the market in North America. Some of the prominent players in this patient registry software market are IBM Corporation (US), IQVIA Holdings (US), OpenText Corporation (Canada), Optum (US), Premier, Inc. (US), ArborMetrix, Inc. (US), FIGmd (US), McKesson Corporation (US), Syneos Health (US), Dacima Software, Inc. (Canada), ifa Systems AG (Germany), Medstreaming- M2S (US), ImageTrend, Inc. (US), Evado Clinical (Australia), WIRB Copernicus Group (US), Global Vision Technologies, Inc. (India), Conduent, Inc. (US), Elekta AB (Sweden), Cedaron (US), LUMEDX (US), Armus Corp (US), Phamax AG (Switzerland), and Versaform Systems Corp (US), ESO Solutions (US) and Ordinal Data, Inc. (US). Urology Devices Market worth $46.4 billion by 2026 - Exclusive Report by MarketsandMarkets™1/17/2022 According to the new market research report "Urology Devices Market by Product ((Dialysis, Endoscopes, Lasers, Lithotripsy, Robotic System), (Guidewires, Catheters, Stents)), Application(Kidney Diseases, Urological Cancer, BPH), End User(Hospital, Dialysis Center, Homecare) - Global Forecast to 2026", published by MarketsandMarkets™, the market is projected to reach USD 46.4 billion by 2026 from USD 38.0 billion in 2021, at a CAGR of 4.1%.
Browse in-depth TOC on "Urology Devices Market" 122 – Tables 36 – Figures 198 – Pages Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173062212 The rising incidence and prevalence of urological conditions drives growth in the urology devices market, growing preference for minimally invasive procedures, and the growing number of hospitals and investments in endoscopy and laparoscopy facilities are among the other factors. Emerging economies such as China and Japan are providing lucrative opportunities for the players operating in the market. The instruments segment accounted for the largest share of the urology devices market, by product segment, in 2020 Based on product, the market is segmented into instruments and consumables & accessories. The instruments segment accounted for the largest share of the market in 2020. This segment includes dialysis devices, endoscopes, laser and lithotripsy devices, robotic systems, endovision and imaging systems, insufflators, endoscopy fluid management systems, and urodynamic systems. The dialysis devices segment accounted for the largest share of the urology instruments market in 2020. The large share of this segment can be attributed to the growing patient pool of CKD due to the rising geriatric population. Urological cancer and BPH segment to register the highest growth rate during the forecast period The urology devices market is segmented into kidney diseases, urological cancer and BPH, pelvic organ prolapse, and other applications based on application. In 2020, the urological cancer and BPH segment accounted for the highest growth rate. This can be attributed to the rising incidence of urological cancers coupled with the growing number of cancer-related surgeries. The hospitals, ASCs, and clinics segment accounted for the largest share of the urology devices market, by end user segment, in 2020 Based on end users, the market is segmented into hospitals, ASCs, and clinics; dialysis centers; and home care settings. In 2020, the hospitals, ASCs, and clinics segment accounted for the largest share of the market. The improving healthcare infrastructure in developing countries such as India, the rising number of target procedures, and the rising number of surgeries are the major factors driving this segments growth. Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=173062212 North America is the largest regional market for urology devices market the market is segmented into five regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the urology devices market. The large share of this region can be attributed to the increasing healthcare expenditure, highly developed healthcare systems in the US and Canada, and increasing prevalence of chronic and lifestyle conditions. The major players operating in this urology devices market are Fresenius Medical Care AG & Co. KGaA (Germany), Baxter International Inc. (US), Boston Scientific Corporation (US), Becton, Dickinson and Company (US), Olympus Corporation (Japan), B. Braun Melsungen AG (Germany), Stryker Corporation (US), KARL STORZ (Germany), Cook Medical (US), Intuitive Surgical (US), Medtronic plc (Ireland), Cardinal Health (US), Teleflex Incorporated (US), Richard Wolf GmbH (Germany), CompactCath (US), Dornier MedTech (Germany), Nikkiso Co., Ltd. (Japan), Balton Sp. z o.o. (Poland), Dialife SA (Switzerland), Maxer Endoscopy GmbH (Germany), Vimex Sp. z o.o. (Poland), Amsino International, Inc. (US), ROCAMED (Monaco), Well Lead Medical Co., Ltd. (China), Medispec (US), Medical Technologies of Georgia (Georgia), EndoMed Systems GmbH (Germany), Hunter Urology (England), J and M Urinary Catheters LLC (US), and Ribbel International Limited (India). Browse Related Reports: Urinary Catheters Market by Product (Indwelling, Intermittent, External), Type (Coated, Uncoated), Application (Urinary Incontinence, Benign Prostate Hyperplasia, General Surgery), Usage (Male, Female), End Users (Hospitals) - Global Forecast to 2025 https://www.marketsandmarkets.com/Market-Reports/urinary-catheter-market-132934629.html |
AuthorWe are providing and consulting the healthcare Industry Research Report. Archives
March 2022
Categories |